These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19670086)

  • 1. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?
    Eker SS; Kirli S; Akkaya C; Cangur S; Sarandol A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):400-8. PubMed ID: 19670086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial.
    Yazicioglu B; Akkaya C; Sarandol A; Akgoz S; Saygin Eker S; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1271-6. PubMed ID: 16820257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder.
    Eker SS; Akkaya C; Sarandol A; Cangur S; Sarandol E; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):955-61. PubMed ID: 18262705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
    Rubio G; San L; López-Muñoz F; Alamo C
    J Affect Disord; 2004 Jul; 81(1):67-72. PubMed ID: 15183602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients.
    Tranter R; Bell D; Gutting P; Harmer C; Healy D; Anderson IM
    J Affect Disord; 2009 Nov; 118(1-3):87-93. PubMed ID: 19250683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
    Millan MJ
    Pharmacol Ther; 2006 May; 110(2):135-370. PubMed ID: 16522330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant effectiveness in severe depression and melancholia.
    Schatzberg AF
    J Clin Psychiatry; 1999; 60 Suppl 4():14-21; discussion 22. PubMed ID: 10086479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].
    Eker SS; Akkaya C; Akgöz S; Sarandöl A; Kirli S
    Turk Psikiyatri Derg; 2005; 16(3):153-63. PubMed ID: 16180148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression.
    Quednow BB; Kühn KU; Stelzenmuelle R; Hoenig K; Maier W; Wagner M
    Psychopharmacology (Berl); 2004 Oct; 175(4):399-406. PubMed ID: 15042278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
    J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
    Sir A; D'Souza RF; Uguz S; George T; Vahip S; Hopwood M; Martin AJ; Lam W; Burt T
    J Clin Psychiatry; 2005 Oct; 66(10):1312-20. PubMed ID: 16259546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
    N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity.
    Bagby RM; Levitan RD; Kennedy SH; Levitt AJ; Joffe RT
    Psychiatry Res; 1999 Jun; 86(3):211-6. PubMed ID: 10482340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.